CTSO

SEC source: 0001144204-17-031785 · v468719_4.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 399,907

F1 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 18,700 RSUs granted on February 24, 2017, (b) 57,000 RSUs granted on June 7, 2016, and (c) 130,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 40,625 RSUs granted on February 24, 2017 and (b) 26,000 RSUs granted on June 7, 2016 and (iii) 127,582 shares of common stock owned by the reporting person (including 3,700 shares of common stock purchased in the open market on June 8, 2017 and reported on this Form 4).

SEC source: 0001144204-17-031784 · v468718_4.xml · nonDerivative · entry 2

Jones Edward Raymond · CIK 0001396246 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,500

F1 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 6,000 RSUs granted on February 24, 2017, (b) 5,000 RSUs granted on June 7, 2016, and (c) 55,000 RSUs granted on April 8, 2015, and (ii) 2,500 shares of common stock purchased by the reporting person in the open market and reported on this Form 4.

SEC source: 0001144204-17-031784 · v468718_4.xml · nonDerivative · entry 1

Jones Edward Raymond · CIK 0001396246 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500

SEC source: 0001144204-17-031283 · v468503_form4.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 396,207

F1 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 18,700 RSUs granted on February 24, 2017, (b) 57,000 RSUs granted on June 7, 2016, and (c) 130,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 40,625 RSUs granted on February 24, 2017 and (b) 26,000 RSUs granted on June 7, 2016 and (iii) 123,882 shares of common stock owned by the reporting person (including 6,300 shares of common stock purchased in the open market on June 5, 2017 and reported on this Form 4).

SEC source: 0001144204-17-028016 · v467237_form4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 9,000

F1 · ownership.nature: These shares are held by the reporting person's husband in a 401(k) account and, as such, the reporting person may be deemed the beneficial owner of such shares.

SEC source: 0001144204-17-011830 · v460707_4.xml · derivative · entry 2

Jones Edward Raymond · CIK 0001396246 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,750

Underlying: Common Stock · 13,750 shares

Expires 2027-02-24

F3 · derivative.exercise_date: Such options were granted pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, which vest in four equal parts at the end of each calendar quarter beginning April 1, 2017.

SEC source: 0001144204-17-011830 · v460707_4.xml · nonDerivative · entry 1

Jones Edward Raymond · CIK 0001396246 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,000

F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan.

F2 · balance_after: Includes (i) 6,000 restricted stock units granted on February 24, 2017 and reported on this Form 4, (ii) 5,000 restricted stock units granted on June 7, 2016, subject to vesting in accordance with the schedule set forth in (1) above and (iii) 55,000 restricted stock units granted on April 8, 2015, subject to vesting in accordance with the schedule set forth in (1) above.

SEC source: 0001144204-17-011840 · v460708_4.xml · derivative · entry 4

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,000

Underlying: Common Stock · 89,000 shares

Expires 2027-02-24

F6 · derivative.exercise_date: Such options were granted pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, and shall vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of CytoSorbents Corporation.

SEC source: 0001144204-17-011840 · v460708_4.xml · nonDerivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,638

F3 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan.

F4 · balance_after: Includes (i) 15,700 restricted stock units granted on February 24, 2017 and reported on this Form 4, (ii) 47,000 restricted stock units granted on June 7, 2016, subject to vesting in accordance with the schedule set forth in (3) above, (iii) 110,000 restricted stock units granted on April 8, 2015, subject to vesting in accordance with the schedule set forth in (3) above and (iv) the restricted stock units described in (2) above.

SEC source: 0001144204-17-011840 · v460708_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,938

F1 · shares: These shares represent restricted stock units which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes (i) 32,813 restricted stock units granted on February 24, 2017 and reported on this Form 4, (ii) 21,000 restricted stock units granted on June 7, 2016, subject to vesting in accordance with the schedule set forth in (1) above and (iii) 2,125 shares of common stock owned by the reporting person.

SEC source: 0001144204-17-011844 · v460713_form4.xml · derivative · entry 3

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2027-02-24

F5 · derivative.exercise_date: Such options were granted pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, and shall vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of CytoSorbents Corporation.

SEC source: 0001144204-17-011844 · v460713_form4.xml · nonDerivative · entry 2

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,562

F3 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan.

F4 · balance_after: Includes (i) 17,900 restricted stock units granted on February 24, 2017 and reported on this Form 4, (ii) 54,000 restricted stock units granted on June 7, 2016, subject to vesting in accordance with the schedule set forth in (3) above, (iii) 125,000 restricted stock units granted on April 8, 2015, subject to vesting in accordance with the schedule set forth in (3) above and (iii) the restricted stock units described in (2) above.

SEC source: 0001144204-17-011844 · v460713_form4.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,662

F1 · shares: These shares represent restricted stock units which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes (i) 35,938 restricted stock units granted on February 24, 2017 and reported on this Form 4, (ii) 23,000 restricted stock units granted on June 7, 2016, subject to vesting in accordance with the schedule set forth in (1) above and (iii) 16,724 shares of common stock owned by the reporting person.

SEC source: 0001144204-17-011838 · v460711_form4.xml · derivative · entry 1

BARTLETT ROBERT HAWES · CIK 0001454496 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2017-02-24

F1 · derivative.exercise_date: Such options were granted pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, and shall vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of CytoSorbents Corporation.

SEC source: 0001144204-17-011829 · v460710_form4.xml · derivative · entry 3

Chan Phillip P. · CIK 0001442786 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,000

Underlying: Common Stock · 112,000 shares

Expires 2027-02-24

F5 · derivative.exercise_date: Such options were granted pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, and shall vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of CytoSorbents Corporation.

SEC source: 0001144204-17-011829 · v460710_form4.xml · nonDerivative · entry 2

Chan Phillip P. · CIK 0001442786 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 389,907

F3 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan.

F4 · balance_after: Includes (i) 18,700 restricted stock units granted on February 24, 2017 and reported on this Form 4, (ii) 57,000 restricted stock units granted on June 7, 2016, subject to vesting in accordance with the schedule set forth in (3) above, (iii) 130,000 restricted stock units granted on April 8, 2015, subject to vesting in accordance with the schedule set forth in (3) above and (iv) the restricted stock units described in (2) above.

SEC source: 0001144204-17-011829 · v460710_form4.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 184,207

F1 · shares: These shares represent restricted stock units which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes (i) 40,625 restricted stock units granted on February 24, 2017 and reported on this Form 4, (ii) 26,000 restricted stock units granted on June 7, 2016, subject to vesting in accordance with the schedule set forth in (1) above and (iii) 117,582 shares of common stock owned by the reporting person.

SEC source: 0001144204-17-011825 · v460705_4.xml · derivative · entry 2

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,750

Underlying: Common Stock · 13,750 shares

Expires 2027-02-24

F3 · derivative.exercise_date: Such options were granted pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, which vest in four equal parts at the end of each calendar quarter beginning April 1, 2017.

SEC source: 0001144204-17-011825 · v460705_4.xml · nonDerivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,000

F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan.

F2 · balance_after: Includes (i) 6,000 restricted stock units granted on February 24, 2017 and reported on this Form 4, (ii) 5,000 restricted stock units granted on June 7, 2016, subject to vesting in accordance with the schedule set forth in (1) above and (iii) 55,000 restricted stock units granted on April 8, 2015, subject to vesting in accordance with the schedule set forth in (1) above.

SEC source: 0001144204-17-011824 · v460709_form4.xml · derivative · entry 2

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,750

Underlying: Common Stock · 13,750 shares

Expires 2027-02-24

F3 · derivative.exercise_date: Such options were granted pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, which vest in four equal parts at the end of each calendar quarter beginning April 1, 2017.

SEC source: 0001144204-17-011824 · v460709_form4.xml · nonDerivative · entry 1

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,000

F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan.

F2 · balance_after: Includes (i) 6,000 restricted stock units granted on February 24, 2017 and reported on this Form 4, (ii) 60,000 restricted stock units granted on June 7, 2017, subject to vesting in accordance with the schedule set forth in (1) above and (iii) 3,000 shares of common stock owned by the reporting person.

SEC source: 0001144204-17-011817 · v460704_4.xml · derivative · entry 2

Kraus Al · CIK 0001368152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,500

Underlying: Common Stock · 27,500 shares

Expires 2027-02-24

F3 · derivative.exercise_date: Such options were granted pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, which vest in four equal parts at the end of each calendar quarter beginning April 1, 2017.

SEC source: 0001144204-17-011817 · v460704_4.xml · nonDerivative · entry 1

Kraus Al · CIK 0001368152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,746

F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan.

F2 · balance_after: Includes (i) 6,000 restricted stock units granted on February 24, 2017 and reported on this Form 4, (ii) 5,000 restricted stock units granted on June 7, 2016, subject to vesting in accordance with the schedule set forth in (1) above, (iii) 55,000 restricted stock units granted on April 8, 2015, subject to vesting in accordance with the schedule set forth in (1) above and (iv) 55,746 shares of common stock owned by the reporting person.

SEC source: 0001144204-17-005348 · v458130_4.xml · derivative · entry 1

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,200

Underlying: Common Stock · 73,200 shares

Expires 2026-06-07

F1 · derivative.exercise_date: On June 7, 2016, the reporting person was granted an option to purchase 91,500 shares of common stock pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, which was to vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of CytoSorbents Corporation (the "Company"). This grant was reported on a Form 4 filed on June 9, 2016. On January 30, 2017, the Board of Directors of the Company determined that 80% of such performance criteria was achieved during 2016, resulting in the vesting of 73,200 shares underlying this option.

SEC source: 0001144204-17-005347 · v458131_4.xml · derivative · entry 1

BARTLETT ROBERT HAWES · CIK 0001454496 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2026-06-07

F1 · derivative.exercise_date: On June 7, 2016, the reporting person was granted an option to purchase 20,000 shares of common stock pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, which was to vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of CytoSorbents Corporation (the "Company"). This grant was reported on a Form 4 filed on June 9, 2016. On January 30, 2017, the Board of Directors of the Company determined that 80% of such performance criteria was achieved during 2016, resulting in the vesting of 16,000 shares underlying this option.

SEC source: 0001144204-17-005342 · v458127_4.xml · derivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,600

Underlying: Common Stock · 77,600 shares

Expires 2026-06-07

F1 · derivative.exercise_date: On June 7, 2016, the reporting person was granted an option to purchase 97,000 shares of common stock pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, which was to vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of CytoSorbents Corporation (the "Company"). This grant was reported on a Form 4 filed on June 9, 2016. On January 30, 2017, the Board of Directors of the Company determined that 80% of such performance criteria was achieved during 2016, resulting in the vesting of 77,600 shares underlying this option.

SEC source: 0001144204-17-005341 · v458129_4.xml · derivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,000

Underlying: Common Stock · 62,000 shares

Expires 2026-06-07

F1 · derivative.exercise_date: On June 7, 2016, the reporting person was granted an option to purchase 77,500 shares of common stock pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, which was to vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of CytoSorbents Corporation (the "Company"). This grant was reported on a Form 4 filed on June 9, 2016. On January 30, 2017, the Board of Directors of the Company determined that 80% of such performance criteria was achieved during 2016, resulting in the vesting of 62,000 shares underlying this option.

SEC source: 0001144204-16-139122 · v454910_4.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 448,103

F1 · kind: Open market purchase.

F2 · balance_after: Includes (i) 126,248 shares of common stock, (ii) 313,855 shares of common stock issuable pursuant to stock options currently exercisable or exercisable within 60 days of the transaction date, and (iii) 8,000 shares of common stock issuable pursuant to warrants currently exercisable or exercisable within 60 days of the transaction date.

SEC source: 0001144204-16-138422 · v454630_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 8,000

F1 · ownership.nature: The shares are held by the reporting person's husband in a 401(k) account, and as such, the reporting person may be deemed the beneficial owner of such shares.